-
Three deaths among 24 adverse events reported to Hiqa under new legislation
07 Nov 2025 20:56 GMT
… three babies were among 24 adverse events referred to the State’s … it received the notifications of adverse events between September 26 and December … providers.
These relate to serious adverse events resulting in unanticipated and unintended …
-
<![CDATA[Managing Adverse Events and Integrating Amivantamab Plus Lazertinib]]>
07 Nov 2025 03:43 GMT
… discuss how effective management of adverse events (AEs) supports successful integration of …
-
<![CDATA[Safety, Tolerability, and Adverse Event Management]]>
06 Nov 2025 21:33 GMT
This discussion addresses the safety and tolerability of first-line targeted therapies for EGFR-mutant NSCLC. Panelists outline the most common adverse effects, including dermatologic, gastrointestinal, and infusion-related reactions. They describe …
-
<![CDATA[Adverse Event Management with Bispecifics]]>
05 Nov 2025 20:44 GMT
Adverse Event Management with Bispecifics
Infection prophylaxis …
-
Oral quadruple receptor agonist confers weight loss with minimal GI adverse events
05 Nov 2025 00:15 GMT
… weeks.
The prevalence of gastrointestinal adverse events was similar between NA-931 …
-
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
08 Nov 2025 16:02 GMT
… most frequently reported treatment-emergent adverse events in the sub-analysis of … and older
SELECTED SAFETY INFORMATION
Adverse Events: In plaque psoriasis, the … dermatitis, headache, pruritus, and influenza.
Adverse Events: In atopic dermatitis, the most …
-
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
08 Nov 2025 15:41 GMT
… U.S. Only treatment-emergent adverse events that were serious or led …
-
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
08 Nov 2025 15:41 GMT
… discontinuation. Discontinuation rates due to adverse events were similar between patients treated …
-
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
08 Nov 2025 14:56 GMT
… with no treatment-related serious adverse events and no ≥Grade 3 changes … -limiting toxicities or serious adverse events related to treatment. Adverse events were generally mild …
-
Effectiveness of Sequential Treatment with Zoledronic Acid Following Discontinuation of Denosumab in Osteoporosis: A Narrative Review
08 Nov 2025 15:29 GMT
… BMD, BTMs, fracture risk, and adverse events. Additionally, it analyzes treatment intervals …